---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-004945"
form_type: "8-K"
ticker: "HRMY"
cik: "0001802665"
company_name: "Harmony Biosciences Holdings, Inc."
filed_at: "2024-04-11T23:59:59+00:00"
generated_at: "2026-06-04T00:08:50.344494+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Harmony Biosciences obtains exclusive license for orexin-2 receptor agonist from Bioprojet

## Summary
- Upfront fee $25.5M; development/regulatory milestones up to $127.5M, sales milestones up to $240M.
- Licensed compound is pre-clinical; IND expected H2 2025 for narcolepsy and other indications.
- Exclusive rights to develop, manufacture, commercialize in US and Latin America.
- Amended 2017 and 2022 LCAs with Bioprojet to remove exclusivity of efforts provisions.

## SEC filing metadata
- accession: 0001558370-24-004945
- form_type: 8-K
- ticker: HRMY
- cik: 0001802665
- company_name: Harmony Biosciences Holdings, Inc.
- filed_at: 2024-04-11T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802665/000155837024004945/0001558370-24-004945-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802665/000155837024004945/hrmy-20240406x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-004945
- JSON: https://secwatch.observer/filing/0001558370-24-004945.json
- Plain text: https://secwatch.observer/filing/0001558370-24-004945.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.